Morfinesulfaat Teva (Morphine Sulfate)

Morphine sulfate binds to μ‑opioid receptors in the brain and spinal cord, activating these receptors to inhibit the release of neurotransmitters that transmit pain signals. This receptor activation reduces neuronal excitability, leading to decreased perception of pain and often producing sedation.

The appropriate dose of Morfinesulfaat Teva is individualized by the prescribing clinician based on factors such as the severity of pain, the patient’s prior opioid exposure, age, organ function, and concurrent medications. No fixed regimen is provided; the prescriber sets the dose and titration schedule.

Morphine sulfate is classified as Pregnancy Category C, meaning risk cannot be ruled out. It may cross the placenta and be excreted in breast milk, potentially causing respiratory depression in the newborn. Use only if the potential benefit justifies the risk, and discuss alternatives with a healthcare professional.

To order Morfinesulfaat Teva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Both morphine sulfate and oxycodone are strong μ‑opioid receptor agonists used for severe pain, but they differ in potency, pharmacokinetics, and side‑effect profiles. Morphine has a longer history of use and is often administered orally in immediate‑release or extended‑release forms, whereas oxycodone may have a slightly higher oral potency and distinct formulation options.

Morfinesulfaat Teva should be stored at ambient temperature below 25 °C (77 °F). Keep the product in its original packaging, protect it from moisture, direct sunlight, and extreme temperatures to maintain stability and potency throughout its shelf life.

Morfinesulfaat Teva is administered orally. The tablets (or oral solution, if supplied) should be swallowed whole with a full glass of water. Dosing intervals and whether the medication is taken with or without food are determined by the prescriber based on individual therapeutic needs.

The most serious risks include respiratory depression, which can be life‑threatening, especially in opioid‑naïve patients or when combined with other depressants; severe hypotension; development of physical dependence or addiction; and rare but serious adrenal insufficiency. Immediate medical attention is required if any of these symptoms occur.

Morphine sulfate is contraindicated in patients with known hypersensitivity to morphine or other opioids, those with severe respiratory depression, uncontrolled asthma or chronic obstructive pulmonary disease, and individuals who have taken monoamine oxidase inhibitors within the past 14 days. Caution is also advised for patients with significant renal or hepatic impairment.